Regent Partners

What Regent Partners does

Regent Partners is a Seoul-headquartered, Korea-licensed venture capital and private equity firm founded in October 2018 (originally as CTK Investment) that operates a cross-border investment platform spanning Seoul and Seattle. The firm invests across early and growth stages in Healthcare and ICT, and has expanded into middle-market M&A and buyout transactions, offering a full-service platform covering Acceleration (initial expansion with management resources), Growth (global management and JV partnerships), and Scale-up (additional funding and scale-up M&A). Its deal flow and sector expertise are anchored by two core strategic corporate GPs: SCL Healthcare Group, a leading Korean diagnostics and clinical pathology platform, and Meere Company (KOSDAQ: 049950), an industrial equipment and surgical robotics manufacturer.

The firm generates revenue through traditional VC/PE fee structures — management fees on committed capital and carried interest on realized profits — supplemented by advisory fees from middle-market M&A mandates. Investment decisions are supported by a management team drawn from investment banking (Barclays, Goldman Sachs, Credit Suisse, BNP Paribas, Cazenove), domestic PE/VC (Woori PE, BRV), and operating startup backgrounds, with senior advisors covering technology (SNU AI and battery research professors), European healthcare (ex-top-tier investment bankers), and Korean M&A law (Kim & Chang senior attorney). Regent Partners is privately held, subject to Korean financial regulatory disclosure, and does not publicly disclose revenue or AUM figures.

Name

Regent Partners

Legal name

Regent Partners

Website

https://regentpartners.vc

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Regent Partners is a Seoul-based, Korea-licensed venture capital and private equity firm investing across early/growth-stage Healthcare and ICT and middle-market M&A, with a Seoul-Seattle cross-border platform backed by corporate GPs SCL Healthcare Group and Meere Company (KOSDAQ: 049950).

Ownership category

akta.pro rank

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Investment Management: Regent Partners generates revenue through traditional venture capital and private equity fee structures, typically including management fees (usually 1-2% of committed capital) and carried interest (typically 20% of profits above a hurdle rate). The firm invests in early and growth-stage companies across Healthcare and ICT, as well as middle-market M&A and buyout transactions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Regent Partners is a premier alternative investment firm that manages venture capital and private equity funds. The firm invests in early and growth-stage companies in the Healthcare and ICT sectors and has expanded into middle-market M&A and buyout transactions. It provides full-service coverage — acceleration, growth, and scale-up support — with active value-add through global networks and operating expertise.

Product overview

Regent Partners is a premier alternative investment firm specializing in venture capital and private equity investments. The firm focuses on early and growth-stage investments across Healthcare and ICT sectors, and has strategically expanded into middle-market M&A and buyout transactions. The company offers a full-service investment platform covering acceleration (initial expansion support with management resources), growth (global management capabilities and JV partnership opportunities), and scale-up (additional funding and scale-up M&A support). The firm has a strong presence in both Korea and the U.S., leveraging global networks and investment experiences to proactively add value to portfolio companies.

Differentiator

Problem solved

Functional benefit

Products and services

• Venture Capital Fund (Early and Growth-Stage) Investment fund providing equity capital and operational support to early and growth-stage companies in the Healthcare and ICT sectors, with active value-add from the team's investment and operating experience.
• Private Equity / Middle-Market M&A and Buyout Fund Private equity fund targeting middle-market M&A and buyout transactions, providing capital, strategic guidance, and scale-up M&A support to portfolio companies.
• Full-Service Investment Platform (Acceleration, Growth, Scale-up) Three-stage investment support platform: Acceleration (initial expansion with management resources), Growth (global management capabilities and JV partnerships for step-up expansion), and Scale-up (additional funding and scale-up M&A support).

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• SCL Healthcare GroupcoreStrategic or Co-development PartnerSCL Healthcare Group is a total healthcare group providing biomarker development, clinical trials, bio logistics, preventive medical checkups, and medical data-based mobile healthcare platforms. The group includes Hanaro Medical Foundation (2nd largest market share in medical checkup service in Korea) and Seoul Clinical Laboratories (largest market share in clinical pathology business in Korea). Regent Partners is backed by SCL's extensive healthcare sector expertise.
• Meere CompanycoreStrategic or Co-development PartnerMeere Company (KOSDAQ: #049950) is one of the leading industrial equipment manufacturers globally, successfully expanded into surgical robots and 3D sensor solutions. Key products include Revo-I (Korea's first laparoscopic surgical robot) and Cube Eye (innovative 3D depth cameras using Time of Flight technology). Regent Partners is backed by Meere's expertise in materials, parts, and equipment sectors including semiconductors and medical devices.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Korea Investment Partners: One of Korea's largest PE/VC firms (subsidiary of Korea Investment Holdings) with broad sector coverage and an established institutional LP base. Directly comparable as a Korean-domiciled alternative investment manager operating across multiple stages and sectors including healthcare and ICT.
• Mirae Asset Venture Investment: Korean VC arm of Mirae Asset Financial Group with broad sector focus including ICT and healthcare. Comparable as a large, established Korean VC/PE firm with sector breadth overlapping Regent's thesis and similar stage positioning from early to growth.
• KDB Capital: VC/PE subsidiary of Korea Development Bank with deep sector coverage and government backing. Comparable in stage focus (early to growth) and Korean institutional fundraising profile, and similarly targets Korean strategic sectors including advanced manufacturing.
• KB Investment: VC/PE arm of KB Financial Group with diversified portfolio across healthcare, ICT, and growth-stage Korean companies. Comparable in scale ambition, sector focus, and Korean institutional LP base.
• Atinum Investment: Independent Korean VC/PE firm with broad sector coverage including healthcare and technology. Comparable as a similarly-sized private Korean manager competing for similar deals and serving similar Korean LP base.
• LB Investment: Korean VC/PE firm with focus on early and growth-stage investments in technology and healthcare. Comparable in stage focus and sector overlap with Regent, and competing for similar Korean institutional LPs.
• BonAngels Venture Partners: Korean early-stage VC firm with focus on ICT and healthcare startups. Comparable in stage focus (early/growth) and Korean deal-sourcing profile, particularly for founders seeking cross-border expansion support.
• Primer (formerly Primer Partners): Korean growth-stage VC firm with technology focus. Comparable in stage positioning (early/growth) and Korean institutional LP base, and operating in similar Series A/B Korean venture rounds.
• D.CAMP: Korean startup accelerator and early-stage investor backed by DGB Daegu Bank. Comparable in early-stage focus and Korean venture ecosystem positioning, with similar value-add support models for portfolio companies.

Emerging players

• Medytox Ventures / Korea Health Industry Development Institute-backed funds: Korean healthcare-specialist VC/PE platforms focusing on biotech, medical devices, and diagnostics. Comparable given Regent's healthcare sector emphasis via SCL Healthcare Group backing, though these players tend to be more sector-specialized than Regent's broader thesis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/regentpartners-vc

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Regent Partners